-
1
-
-
41349099104
-
Cancer statistics, 2008
-
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
-
(2008)
CA Cancer J Clin
, vol.58
, pp. 71-96
-
-
Jemal, A.1
Siegel, R.2
Ward, E.3
Hao, Y.4
Xu, J.5
Murray, T.6
Thun, M.J.7
-
2
-
-
34347220473
-
Defining the role of mTOR in cancer
-
Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell 2007;12:9-22.
-
(2007)
Cancer Cell
, vol.12
, pp. 9-22
-
-
Guertin, D.A.1
Sabatini, D.M.2
-
3
-
-
31444434449
-
mTOR signaling: Implications for cancer and anticancer therapy
-
Petroulakis E, Mamane Y, Le Bacquer O, Shahbazian D, Sonenberg N. mTOR signaling: implications for cancer and anticancer therapy. Br J Cancer 2006;94:195-9.
-
(2006)
Br J Cancer
, vol.94
, pp. 195-199
-
-
Petroulakis, E.1
Mamane, Y.2
Le Bacquer, O.3
Shahbazian, D.4
Sonenberg, N.5
-
4
-
-
2342483301
-
Rapamycin inhibits telomerase activity by decreasing the hTERT mRNA level in endometrial cancer cells
-
Zhou C, Gehrig PA, Whang YE, Boggess JF. Rapamycin inhibits telomerase activity by decreasing the hTERT mRNA level in endometrial cancer cells. Mol Cancer Ther 2003;2:789-95.
-
(2003)
Mol Cancer Ther
, vol.2
, pp. 789-795
-
-
Zhou, C.1
Gehrig, P.A.2
Whang, Y.E.3
Boggess, J.F.4
-
5
-
-
0031833563
-
Mammalian target of rapamycin: Immunosuppressive drugs uncover a novel pathway of cytokine receptor signaling
-
Abraham RT. Mammalian target of rapamycin: immunosuppressive drugs uncover a novel pathway of cytokine receptor signaling. Curr Opin Immunol 1998;10:330-6.
-
(1998)
Curr Opin Immunol
, vol.10
, pp. 330-336
-
-
Abraham, R.T.1
-
6
-
-
58149385663
-
Deforolimus (AP23573) a novel mTOR inhibitor in clinical development
-
Mita M, Sankhala K, Abdel-Karim I, Mita A, Giles F. Deforolimus (AP23573) a novel mTOR inhibitor in clinical development. Expert Opin Investig Drugs 2008;17:1947-54.
-
(2008)
Expert Opin Investig Drugs
, vol.17
, pp. 1947-1954
-
-
Mita, M.1
Sankhala, K.2
Abdel-Karim, I.3
Mita, A.4
Giles, F.5
-
8
-
-
14944385644
-
Immunohistochemical expression of E-cadherin and β-catenin in the normal and malignant human endometrium: An inverse correlation between E-cadherin and nuclear β-catenin expression
-
Shih HC, Shiozawa T, Miyamoto T, Kashima H, Feng YZ, Kurai M, Konishi I. Immunohistochemical expression of E-cadherin and β-catenin in the normal and malignant human endometrium: an inverse correlation between E-cadherin and nuclear β-catenin expression. Anticancer Res 2004;24:3843-50.
-
(2004)
Anticancer Res
, vol.24
, pp. 3843-3850
-
-
Shih, H.C.1
Shiozawa, T.2
Miyamoto, T.3
Kashima, H.4
Feng, Y.Z.5
Kurai, M.6
Konishi, I.7
-
9
-
-
20244365941
-
The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation
-
Beuvink I, Boulay A, Fumagalli S, Zilbermann F, Ruetz S, O'Reilly T, Natt F, Hall J, Lane HA, Thomas G. The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell 2005;120:747-59.
-
(2005)
Cell
, vol.120
, pp. 747-759
-
-
Beuvink, I.1
Boulay, A.2
Fumagalli, S.3
Zilbermann, F.4
Ruetz, S.5
O'Reilly, T.6
Natt, F.7
Hall, J.8
Lane, H.A.9
Thomas, G.10
-
10
-
-
26844545448
-
Overcoming cisplatin resistance by mTOR inhibitor in lung cancer
-
Wu C, Wangpaichitr M, Feun L, Kuo MT, Robles C, Lampidis T, Savaraj N. Overcoming cisplatin resistance by mTOR inhibitor in lung cancer. Mol Cancer 2005;4:25.
-
(2005)
Mol Cancer
, vol.4
, pp. 25
-
-
Wu, C.1
Wangpaichitr, M.2
Feun, L.3
Kuo, M.T.4
Robles, C.5
Lampidis, T.6
Savaraj, N.7
-
11
-
-
6044259204
-
Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells
-
Mondesire WH, Jian W, Zhang H, Ensor J, Hung MC, Mills GB, Meric-Bernstam F. Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells. Clin Cancer Res 2004;10:7031-42.
-
(2004)
Clin Cancer Res
, vol.10
, pp. 7031-7042
-
-
Mondesire, W.H.1
Jian, W.2
Zhang, H.3
Ensor, J.4
Hung, M.C.5
Mills, G.B.6
Meric-Bernstam, F.7
-
12
-
-
34547130295
-
RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model
-
Mabuchi S, Altomare DA, Cheung M, Zhang L, Poulikakos PI, Hensley HH, Schilder RJ, Ozols RF, Testa JR. RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model. Clin Cancer Res 2007;13:4261-70.
-
(2007)
Clin Cancer Res
, vol.13
, pp. 4261-4270
-
-
Mabuchi, S.1
Altomare, D.A.2
Cheung, M.3
Zhang, L.4
Poulikakos, P.I.5
Hensley, H.H.6
Schilder, R.J.7
Ozols, R.F.8
Testa, J.R.9
-
13
-
-
33646197484
-
Inhibition of the mammalian target of rapamycin (mTOR) by rapamycin increases chemosensitivity of CaSki cells to paclitaxel
-
Faried LS, Faried A, Kanuma T, Nakazato T, Tamura T, Kuwano H, Minegishi T. Inhibition of the mammalian target of rapamycin (mTOR) by rapamycin increases chemosensitivity of CaSki cells to paclitaxel. Eur J Cancer 2006;42:934-47.
-
(2006)
Eur J Cancer
, vol.42
, pp. 934-947
-
-
Faried, L.S.1
Faried, A.2
Kanuma, T.3
Nakazato, T.4
Tamura, T.5
Kuwano, H.6
Minegishi, T.7
-
14
-
-
0035866358
-
Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy
-
Geoerger B, Kerr K, Tang CB, Fung KM, Powell B, Sutton LN, Phillips PC, Janss AJ. Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy. Cancer Res 2001;61:1527-32.
-
(2001)
Cancer Res
, vol.61
, pp. 1527-1532
-
-
Geoerger, B.1
Kerr, K.2
Tang, C.B.3
Fung, K.M.4
Powell, B.5
Sutton, L.N.6
Phillips, P.C.7
Janss, A.J.8
-
15
-
-
0032006059
-
Microtubules and actin filaments: Dynamic targets for cancer chemotherapy
-
Jordan MA, Wilson L. Microtubules and actin filaments: dynamic targets for cancer chemotherapy. Curr Opin Cell Biol 1998;10:123-30.
-
(1998)
Curr Opin Cell Biol
, vol.10
, pp. 123-130
-
-
Jordan, M.A.1
Wilson, L.2
-
16
-
-
33644520595
-
Systematic review of systemic therapy for advanced or recurrent endometrial cancer
-
Carey MS, Gawlik C, Fung-Kee-Fung M, Chambers A, Oliver T. Systematic review of systemic therapy for advanced or recurrent endometrial cancer. Gynecol Oncol 2006;101:158-67.
-
(2006)
Gynecol Oncol
, vol.101
, pp. 158-167
-
-
Carey, M.S.1
Gawlik, C.2
Fung-Kee-Fung, M.3
Chambers, A.4
Oliver, T.5
-
17
-
-
33646934663
-
Old and new perspectives in the pharmacological treatment of advanced or recurrent endometrial cancer: Hormonal therapy, chemotherapy and molecularly targeted therapies
-
Gadducci A, Cosio S, Genazzani AR. Old and new perspectives in the pharmacological treatment of advanced or recurrent endometrial cancer: hormonal therapy, chemotherapy and molecularly targeted therapies. Crit Rev Oncol Hematol 2006;58:242-56.
-
(2006)
Crit Rev Oncol Hematol
, vol.58
, pp. 242-256
-
-
Gadducci, A.1
Cosio, S.2
Genazzani, A.R.3
-
18
-
-
0037365456
-
Endometrial cancer: Experimental models useful for studies on molecular aspects of endometrial cancer and carcinogenesis
-
Vollmer G. Endometrial cancer: experimental models useful for studies on molecular aspects of endometrial cancer and carcinogenesis. Endocr Relat Cancer 2003;10:23-42.
-
(2003)
Endocr Relat Cancer
, vol.10
, pp. 23-42
-
-
Vollmer, G.1
-
19
-
-
33747597588
-
Endometrial cancer cells as models to study uterine receptivity
-
Kuramoto H, Nishida M, editors, Tokyo:Springer-Verlag
-
Lessey BA, Vendrov AE, Yuan L. Endometrial cancer cells as models to study uterine receptivity. In: Kuramoto H, Nishida M, editors. Cell and molcular biology of endometrial carcinoma. Tokyo:Springer-Verlag, 2003.267-79.
-
(2003)
Cell and molcular biology of endometrial carcinoma
, pp. 267-279
-
-
Lessey, B.A.1
Vendrov, A.E.2
Yuan, L.3
-
20
-
-
0343415646
-
Quantitation of hTERT gene expression in sporadic breast tumors with a real-time reverse transcription-polymerase chain reaction assay
-
Bieche I, Nogues C, Paradis V, Olivi M, Bedossa P, Lidereau R, Vidaud M. Quantitation of hTERT gene expression in sporadic breast tumors with a real-time reverse transcription-polymerase chain reaction assay. Clin Cancer Res 2000;6:452-9.
-
(2000)
Clin Cancer Res
, vol.6
, pp. 452-459
-
-
Bieche, I.1
Nogues, C.2
Paradis, V.3
Olivi, M.4
Bedossa, P.5
Lidereau, R.6
Vidaud, M.7
-
21
-
-
0021118703
-
Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors
-
Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
-
(1984)
Adv Enzyme Regul
, vol.22
, pp. 27-55
-
-
Chou, T.C.1
Talalay, P.2
-
22
-
-
0030915898
-
Rapamycin suppresses 5′TOP mRNA translation through inhibition of p70s6k
-
Jefferies HB, Fumagalli S, Dennis PB, Reinhard C, Pearson RB, Thomas G. Rapamycin suppresses 5′TOP mRNA translation through inhibition of p70s6k. Embo J 1997;16:3693-704.
-
(1997)
Embo J
, vol.16
, pp. 3693-3704
-
-
Jefferies, H.B.1
Fumagalli, S.2
Dennis, P.B.3
Reinhard, C.4
Pearson, R.B.5
Thomas, G.6
-
23
-
-
0035312747
-
Regulation of translation initiation by FRAP/mTOR
-
Gingras AC, Raught B, Sonenberg N. Regulation of translation initiation by FRAP/mTOR. Genes Dev 2001;15:807-26.
-
(2001)
Genes Dev
, vol.15
, pp. 807-826
-
-
Gingras, A.C.1
Raught, B.2
Sonenberg, N.3
-
24
-
-
0028197298
-
Dominant negative mutants of mammalian translation initiation factor eIF-4A define a critical role for eIF-4F in cap-dependent and capin-dependent initiation of translation
-
Pause A, Methot N, Svitkin Y, Merrick WC, Sonenberg N. Dominant negative mutants of mammalian translation initiation factor eIF-4A define a critical role for eIF-4F in cap-dependent and capin-dependent initiation of translation. Embo J 1994;13:1205-15.
-
(1994)
Embo J
, vol.13
, pp. 1205-1215
-
-
Pause, A.1
Methot, N.2
Svitkin, Y.3
Merrick, W.C.4
Sonenberg, N.5
-
25
-
-
0141996464
-
Microtubules, microtubule-interfering agents and apoptosis
-
Mollinedo F, Gajate C. Microtubules, microtubule-interfering agents and apoptosis. Apoptosis 2003;8:413-50.
-
(2003)
Apoptosis
, vol.8
, pp. 413-450
-
-
Mollinedo, F.1
Gajate, C.2
-
26
-
-
43749116022
-
Antiproliferative effects of rapamycin as a single agent and in combination with carboplatin and paclitaxel in head and neck cancer cell lines
-
Aissat N, Le Tourneau C, Ghoul A, Serova M, Bieche I, Lokiec F, Raymond E, Faivre S. Antiproliferative effects of rapamycin as a single agent and in combination with carboplatin and paclitaxel in head and neck cancer cell lines. Cancer Chemother Pharmacol 2008;62:305-13.
-
(2008)
Cancer Chemother Pharmacol
, vol.62
, pp. 305-313
-
-
Aissat, N.1
Le Tourneau, C.2
Ghoul, A.3
Serova, M.4
Bieche, I.5
Lokiec, F.6
Raymond, E.7
Faivre, S.8
-
27
-
-
7944223834
-
Targeting the mammalian target of rapamycin (mTOR): A new approach to treating cancer
-
Chan S. Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer. Br J Cancer 2004;91:1420-4.
-
(2004)
Br J Cancer
, vol.91
, pp. 1420-1424
-
-
Chan, S.1
-
28
-
-
0037473081
-
Paclitaxel induces inactivation of p70 S6 kinase and phosphorylation of Thr421 and Ser424 via multiple signaling pathways in mitosis
-
Le XF, Hittelman WN, Liu J, McWatters A, Li C, Mills GB, Bast RC, Jr. Paclitaxel induces inactivation of p70 S6 kinase and phosphorylation of Thr421 and Ser424 via multiple signaling pathways in mitosis. Oncogene 2003;22:484-97.
-
(2003)
Oncogene
, vol.22
, pp. 484-497
-
-
XF, L.1
Hittelman, W.N.2
Liu, J.3
McWatters, A.4
Li, C.5
Mills, G.B.6
Bast Jr, R.C.7
-
29
-
-
0029902281
-
p70 S6 kinase sensitivity to rapamycin is eliminated by amino acid substitution of Thr229
-
Sugiyama H, Papst P, Gelfand EW, Terada N. p70 S6 kinase sensitivity to rapamycin is eliminated by amino acid substitution of Thr229. J Immunol 1996;157:656-60.
-
(1996)
J Immunol
, vol.157
, pp. 656-660
-
-
Sugiyama, H.1
Papst, P.2
Gelfand, E.W.3
Terada, N.4
-
30
-
-
32644476664
-
Rapamycin inhibits hTERT telomerase mRNA expression, independent of cell cycle arrest
-
Bae-Jump VL, Zhou C, Gehrig PA, Whang YE, Boggess JF. Rapamycin inhibits hTERT telomerase mRNA expression, independent of cell cycle arrest. Gynecol Oncol 2006;100:487-94.
-
(2006)
Gynecol Oncol
, vol.100
, pp. 487-494
-
-
Bae-Jump, V.L.1
Zhou, C.2
Gehrig, P.A.3
Whang, Y.E.4
Boggess, J.F.5
-
31
-
-
0035859956
-
p70S6 kinase signals cell survival as well as growth, inactivating the pro-apoptotic molecule BAD
-
Harada H, Andersen JS, Mann M, Terada N, Korsmeyer SJ. p70S6 kinase signals cell survival as well as growth, inactivating the pro-apoptotic molecule BAD. Proc Natl Acad Sci USA 2001;98:9666-70.
-
(2001)
Proc Natl Acad Sci USA
, vol.98
, pp. 9666-9670
-
-
Harada, H.1
Andersen, J.S.2
Mann, M.3
Terada, N.4
Korsmeyer, S.J.5
-
33
-
-
0031895821
-
Telomerase activity in the female reproductive tract and neoplasms
-
Yokoyama Y, Takahashi Y, Shinohara A, Lian Z, Tamaya T. Telomerase activity in the female reproductive tract and neoplasms. Gynecol Oncol 1998;68:145-9.
-
(1998)
Gynecol Oncol
, vol.68
, pp. 145-149
-
-
Yokoyama, Y.1
Takahashi, Y.2
Shinohara, A.3
Lian, Z.4
Tamaya, T.5
-
34
-
-
0031013130
-
Telomerase activity in gynecologic tumors
-
Zheng PS, Iwasaka T, Yamasaki F, Ouchida M, Yokoyama M, Nakao Y, Fukuda K, Matsuyama T, Sugimori H. Telomerase activity in gynecologic tumors. Gynecol Oncol 1997;64:171-5.
-
(1997)
Gynecol Oncol
, vol.64
, pp. 171-175
-
-
Zheng, P.S.1
Iwasaka, T.2
Yamasaki, F.3
Ouchida, M.4
Yokoyama, M.5
Nakao, Y.6
Fukuda, K.7
Matsuyama, T.8
Sugimori, H.9
-
35
-
-
0037308546
-
Simultaneous targeting of telomeres and telomerase as a cancer therapeutic approach
-
Mo Y, Gan Y, Song S, Johnston J, Xiao X, Wientjes MG, Au JL. Simultaneous targeting of telomeres and telomerase as a cancer therapeutic approach. Cancer Res 2003;63:579-85.
-
(2003)
Cancer Res
, vol.63
, pp. 579-585
-
-
Mo, Y.1
Gan, Y.2
Song, S.3
Johnston, J.4
Xiao, X.5
Wientjes, M.G.6
Au, J.L.7
-
36
-
-
0032614548
-
Cell-killing by paclitaxel in a metastatic murine melanoma cell line is mediated by extensive telomere erosion with no decrease in telomerase activity
-
Multani AS, Li C, Ozen M, Imam AS, Wallace S, Pathak S. Cell-killing by paclitaxel in a metastatic murine melanoma cell line is mediated by extensive telomere erosion with no decrease in telomerase activity. Oncol Rep 1999;6:39-44.
-
(1999)
Oncol Rep
, vol.6
, pp. 39-44
-
-
Multani, A.S.1
Li, C.2
Ozen, M.3
Imam, A.S.4
Wallace, S.5
Pathak, S.6
-
37
-
-
0035959805
-
Damaged microtubules can inactivate BCL-2 by means of the mTOR kinase
-
Calastretti A, Bevilacqua A, Ceriani C, Vigano S, Zancai P, Capaccioli S, Nicolin A. Damaged microtubules can inactivate BCL-2 by means of the mTOR kinase. Oncogene 2001;20:6172-80.
-
(2001)
Oncogene
, vol.20
, pp. 6172-6180
-
-
Calastretti, A.1
Bevilacqua, A.2
Ceriani, C.3
Vigano, S.4
Zancai, P.5
Capaccioli, S.6
Nicolin, A.7
-
38
-
-
74049096986
-
Synergistic effect of cisplatin and rapamycin in endometrial cancer cells
-
Bae-Jump V, Zhou C, Boggess JB, Whang YE, Gehrig PA. Synergistic effect of cisplatin and rapamycin in endometrial cancer cells. Gynecologic Oncology 2007;104(suppl. 1):S54.
-
(2007)
Gynecologic Oncology
, vol.104
, Issue.SUPPL. 1
-
-
Bae-Jump, V.1
Zhou, C.2
Boggess, J.B.3
Whang, Y.E.4
Gehrig, P.A.5
-
39
-
-
35948965312
-
Valproic acid enhances tubulin acetylation and apoptotic activity of paclitaxel on anaplastic thyroid cancer cell lines
-
Catalano MG, Poli R, Pugliese M, Fortunati N, Boccuzzi G. Valproic acid enhances tubulin acetylation and apoptotic activity of paclitaxel on anaplastic thyroid cancer cell lines. Endocr Relat Cancer 2007;14:839-45.
-
(2007)
Endocr Relat Cancer
, vol.14
, pp. 839-845
-
-
Catalano, M.G.1
Poli, R.2
Pugliese, M.3
Fortunati, N.4
Boccuzzi, G.5
-
40
-
-
0036731055
-
Histone deacetylase inhibitors all induce p21 but differentially cause tubulin acetylation, mitotic arrest, and cytotoxicity
-
Blagosklonny MV, Robey R, Sackett DL, Du L, Traganos F, Darzynkiewicz Z, Fojo T, Bates SE. Histone deacetylase inhibitors all induce p21 but differentially cause tubulin acetylation, mitotic arrest, and cytotoxicity. Mol Cancer Ther 2002;1:937-41.
-
(2002)
Mol Cancer Ther
, vol.1
, pp. 937-941
-
-
Blagosklonny, M.V.1
Robey, R.2
Sackett, D.L.3
Du, L.4
Traganos, F.5
Darzynkiewicz, Z.6
Fojo, T.7
Bates, S.E.8
-
41
-
-
4143066849
-
Bcl-2 phosphorylation and apoptosis activated by damaged microtubules require mTOR and are regulated by Akt
-
Asnaghi L, Calastretti A, Bevilacqua A, D'Agnano I, Gatti G, Canti G, Delia D, Capaccioli S, Nicolin A. Bcl-2 phosphorylation and apoptosis activated by damaged microtubules require mTOR and are regulated by Akt. Oncogene 2004;23:5781-91.
-
(2004)
Oncogene
, vol.23
, pp. 5781-5791
-
-
Asnaghi, L.1
Calastretti, A.2
Bevilacqua, A.3
D'Agnano, I.4
Gatti, G.5
Canti, G.6
Delia, D.7
Capaccioli, S.8
Nicolin, A.9
-
43
-
-
46149092748
-
Role of mTOR in anticancer drug resistance: Perspectives for improved drug treatment
-
Jiang BH, Liu LZ. Role of mTOR in anticancer drug resistance: perspectives for improved drug treatment. Drug Resist Updat 2008;11:63-76.
-
(2008)
Drug Resist Updat
, vol.11
, pp. 63-76
-
-
Jiang, B.H.1
Liu, L.Z.2
-
44
-
-
12344288380
-
Akt up-regulation increases resistance to microtubule-directed chemotherapeutic agents through mammalian target of rapamycin
-
VanderWeele DJ, Zhou R, Rudin CM. Akt up-regulation increases resistance to microtubule-directed chemotherapeutic agents through mammalian target of rapamycin. Mol Cancer Ther 2004;3:1605-13.
-
(2004)
Mol Cancer Ther
, vol.3
, pp. 1605-1613
-
-
VanderWeele, D.J.1
Zhou, R.2
Rudin, C.M.3
-
45
-
-
69249085764
-
Synergistic effect of rapamycin and cisplatin in endometrial cancer cells
-
Bae-Jump VL, Zhou C, Boggess JF, Gehrig PA. Synergistic effect of rapamycin and cisplatin in endometrial cancer cells. Cancer 2009; 115:3887-96.
-
(2009)
Cancer
, vol.115
, pp. 3887-3896
-
-
Bae-Jump, V.L.1
Zhou, C.2
Boggess, J.F.3
Gehrig, P.A.4
-
46
-
-
4444346646
-
AKT involvement in cisplatin chemoresistance of human uterine cancer cells
-
Gagnon V, Mathieu I, Sexton E, Leblanc K, Asselin E. AKT involvement in cisplatin chemoresistance of human uterine cancer cells. Gynecol Oncol 2004;94:785-95.
-
(2004)
Gynecol Oncol
, vol.94
, pp. 785-795
-
-
Gagnon, V.1
Mathieu, I.2
Sexton, E.3
Leblanc, K.4
Asselin, E.5
|